Contineum Therapeutics, Inc. (CTNM) vs Puma Biotechnology, Inc. (PBYI)
A side-by-side comparison of Contineum Therapeutics, Inc. and Puma Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTNM
Contineum Therapeutics, Inc.
$12.48HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
PBYI
Puma Biotechnology, Inc.
$9.56HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — CTNM vs PBYI
growth of $100 · dividends reinvested · last 2yCTNM -17.4% (-9.1%/yr)PBYI +80.7% (+34.4%/yr)PBYI compounded faster over this window
CTNM PBYI
CTNM vs PBYI: by the numbers
- •PBYI is the larger company ($486M vs $470M market cap).
- •PBYI is profitable (11.55% net margin) while CTNM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | CTNM | PBYI |
|---|---|---|
| P/E ratio | N/A | 18.51 |
| Forward P/E | N/A | 25.15 |
| P/S ratio | N/A | 2.10 |
| P/B ratio | 1.96 | 3.51 |
| EV / EBITDA | N/A | 10.47 |
| FCF yield | N/A | 8.45% |
Profitability
| Metric | CTNM | PBYI |
|---|---|---|
| Gross margin | 0.00% | 74.83% |
| Operating margin | 0.00% | 13.16% |
| Net margin | 0.00% | 11.55% |
| ROE | -24.02% | 19.28% |
| ROIC | -27.22% | 18.26% |
Growth (annualized)
| Metric | CTNM | PBYI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 0.29% |
| FCF CAGR (5Y) | N/A | 90.51% |
| Total return CAGR (5Y) | N/A | 9.26% |
Frequently asked
- Is CTNM or PBYI more profitable?
- PBYI runs the higher net margin — CTNM at 0.00% versus PBYI at 11.55%.
Go deeper
Dig into the metrics
Puma Biotechnology P/E ratioContineum Therapeutics ROEPuma Biotechnology ROEContineum Therapeutics operating marginPuma Biotechnology operating marginContineum Therapeutics revenue growthPuma Biotechnology revenue growthContineum Therapeutics free cash flowPuma Biotechnology free cash flow
Contineum Therapeutics & Puma Biotechnology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.